Indazolyl derivatives useful as potassium channel modulating agents
Potassium channel modulating agents of Formula Ia or Ib and enantiomers and mixtures enantiomers and N-oxides thereof, and pharmaceutically acceptable salts thereof, and their use in the preparation of pharmaceutical compositions. Also, pharmaceutical compositions useful for the treatment or alleviation of diseases or disorders associated with the activity of potassium channels, e.g., respiratory diseases, epilepsy, convulsions, vascular spasms, coronary artery spasms, renal disorders, polycystic kidney disease, bladder spasms, urinary incontinence, bladder outflow obstruction, irritable bowel syndrome, gastrointestinal dysfunction, secretory diarrhoea, ischaemia, cerebral ischaemia, ischaemic heart disease, angina pectoris, coronary heart disease, traumatic brain injury, psychosis, schizophrenia, anxiety, depression, dementia, memory and attention deficits, Alzheimer's disease, dysmenorrhea, narcolepsy, Reynaud's disease, intermittent claudication, Sjorgren's syndrome, migraine, arrhythmia, hypertension, absence seizures, myotonic muscle dystrophia, xerostomi, diabetes type II, hyperinsulinemia, premature labor, baldness, cancer, immune suppression, or pain.
1. A compound of Formula Ia or Ib
an enantiomer or a mixture of its enantiomers, an N-oxide thereof, or a pharmaceutically acceptable salt thereof, wherein
n is 0, 1, 2 or 3;
X represents O, S or NR′; wherein R′ represents hydrogen, alkyl, cycloalkyl or cycloalkyl-alkyl;
Y represents alkyl, alkyl-cycloalkyl, cycloalkyl, cycloalkyl-alkyl, amino-alkyl, alkyl-amino, alkyl-amino-alkyl, hydroxy-alkyl, alkoxy-alkyl, alkenyl, or phenyl, which phenyl may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, amino-alkyl, alkyl-amino, alkyl-amino-alkyl, hydroxy-alkyl, alkoxy-alkyl, cycloalkyl, cycloalkyl-alkyl, alkenyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, cyano, nitro and amino;
A′ represents CR 2 , wherein R 2 is as defined below; and A″ represents N; and
R 1 , R 2 , R 3 and R 4 , independently of each other, represent hydrogen, alkyl, amino-alkyl, alkyl-amino, alkyl-amino-alkyl, alkyl-carbonyl-amino, hydroxy-alkyl, alkoxy-alkyl, cycloalkyl, cycloalkyl-alkyl, alkenyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, alkoxy-carbonyl, cyano, nitro and amino; or R 1 and R 2 together with the heteroaromatic ring to which they are attached form a benzo-fused ring; and R 3 and R 4 , independently of each other, represent hydrogen, alkyl, amino-alkyl, alkyl-amino, alkyl-amino-alkyl, alkyl-carbonyl-amino, hydroxy-alkyl, alkoxy-alkyl, cycloalkyl, cycloalkyl-alkyl, alkenyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, alkoxy-carbonyl, cyano, nitro and amino.
2. The compound of claim 1 , being a compound of Formula Ia, an enantiomer or a mixture of its enantiomers, an N-oxide thereof, or a pharmaceutically acceptable salt thereof.
3. The compound of claim 1 , an enantiomer or a mixture of its enantiomers, an N-oxide thereof, or a pharmaceutically acceptable salt thereof, wherein n is 0 or 1.
4. The compound of claim 1 , an enantiomer or a mixture of its enantiomers, an N-oxide thereof, or a pharmaceutically acceptable salt thereof, wherein X represents NR′; wherein R′ represents hydrogen, alkyl, cycloalkyl or cycloalkyl-alkyl.
5. The compound of claim 1 , an enantiomer or a mixture of its enantiomers, an N-oxide thereof, or a pharmaceutically acceptable salt thereof, wherein Y represents alkyl, alkyl-cycloalkyl, cycloalkyl, or phenyl, which phenyl may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, cycloalkyl, halo, haloalkyl, haloalkoxy, cyano, nitro and amino.
6. The compound of claim 1 , an enantiomer or a mixture of its enantiomers, an N-oxide thereof, or a pharmaceutically acceptable salt thereof, wherein R 2 represents hydrogen, alkyl or cycloalkyl.
7. The compound of claim 1 , an enantiomer or a mixture of its enantiomers, an N-oxide thereof, or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 and R 4 , independently of each other, represent hydrogen, alkyl, amino-alkyl, alkyl-amino, alkyl-amino-alkyl, alkyl-carbonyl-amino, hydroxy-alkyl, alkoxy-alkyl, cycloalkyl, cycloalkyl-alkyl, alkenyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, alkoxy-carbonyl, cyano, nitro and amino.
8. The compound of claim 1 , which is
(4-Chloro-phenyl)-(2-indazol-2-yl-6-methyl-pyrimidin-4-yl)-amine;
(4-Chloro-phenyl)-(2-indazol-1-yl-6-methyl-pyrimidin-4-yl)-amine;
Cyclohexyl-(2-indazol-1-yl-quinazolin-4-yl)-amine;
Cyclohexyl-(2-indazol-1-yl-pyrimidin-4-yl)-amine;
Cyclohexyl-(2-indazol-1-yl-6-methyl-pyrimidin-4-yl)-amine;
(4-Chloro-benzyl)-(2-indazol-2-yl-pyrimidin-4-yl)-amine;
(4-Chloro-benzyl)-(2-indazol-1-yl-pyrimidin-4-yl)-amine;
(4-Chloro-phenyl)-[2-(6-nitro-indazol-2-yl)-pyrimidin-4-yl]-amine;
(4-Chloro-phenyl)-[2-(5-nitro-indazol-2-yl)-pyrimidin-4-yl]-amine;
N-(4-Chloro-phenyl)-2-indazol-2-yl-pyrimidine-4,5-diamine;
2-[4-(4-Chloro-phenylamino)-pyrimidin-2-yl]-2H-indazol-6-ylamine;
N-{2-[4-(4-Chloro-phenylamino)-pyrimidin-2-yl]-2H-indazol-6-yl}-acetamide; or
N-{2-[4-(4-Chloro-phenylamino)-pyrimidin-2-yl]-2H-indazol-5-yl}-acetamide;
an enantiomer or a mixture of its enantiomers, an N-oxide thereof, or a pharmaceutically acceptable salt thereof.
9. A pharmaceutical composition comprising a therapeutically-effective amount of the compound according to claim 1 , an enantiomer or a mixture of its enantiomers, an N-oxide thereof, or a pharmaceutically-acceptable addition salt thereof, together with at least one pharmaceutically-acceptable carrier or diluent.
10. The compound of claim 1 , being a compound of Formula Ib, an enantiomer or a mixture of its enantiomers, an N-oxide thereof, or a pharmaceutically acceptable salt thereof.
11. The compound of claim 1 , an enantiomer or a mixture of its enantiomers, an N-oxide thereof, or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 together with the heteroaromatic ring to which they are attached form a benzo-fused ring; and R 3 and R 4 , independently of each other, represent hydrogen, alkyl, amino-alkyl, alkyl-amino, alkyl-amino-alkyl, hydroxy-alkyl, alkoxy-alkyl, cycloalkyl, cycloalkyl-alkyl, alkenyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, alkoxy-carbonyl, cyano, nitro and amino.
12. The compound of claim 6 , wherein R 2 is hydrogen, methyl, ethyl or propyl.
13. A compound of one of the following Formulas:
an enantiomer or a mixture of its enantiomers, an N-oxide thereof, or a pharmaceutically acceptable salt thereof, wherein
n is 0, 1, 2 or 3;
X represents O, S or NR′; wherein R′ represents hydrogen, alkyl, cycloalkyl or cycloalkyl-alkyl;
Y represents alkyl, alkyl-cycloalkyl, cycloalkyl, cycloalkyl-alkyl, amino-alkyl, alkyl-amino, alkyl-amino-alkyl, hydroxy-alkyl, alkoxy-alkyl, alkenyl, or phenyl, which phenyl may optionally be substituted one or more times with substituents selected from the group consisting of alkyl, amino-alkyl, alkyl-amino, alkyl-amino-alkyl, hydroxy-alkyl, alkoxy-alkyl, cycloalkyl, cycloalkyl-alkyl, alkenyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, cyano, nitro and amino; and
R 1 , R 2 , R 3 and R 4 , independently of each other, represent hydrogen, alkyl, amino-alkyl, alkyl-amino, alkyl-amino-alkyl, alkyl-carbonyl-amino, hydroxy-alkyl, alkoxy-alkyl, cycloalkyl, cycloalkyl-alkyl, alkenyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, alkoxy-carbonyl, cyano, nitro and amino; and R 3 and R 4 , independently of each other, represent hydrogen, alkyl, amino-alkyl, alkyl-amino, alkyl-amino-alkyl, alkyl-carbonyl-amino, hydroxy-alkyl, alkoxy-alkyl, cycloalkyl, cycloalkyl-alkyl, alkenyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, alkoxy-carbonyl, cyano, nitro and amino.
14. The compound of claim 13 , an enantiomer or a mixture of its enantiomers, an N-oxide thereof, or a pharmaceutically acceptable salt thereof wherein X is NH and Y is a phenyl group substituted with a halogen atom.
15. The compound of claim 14 , an enantiomer or a mixture of its enantiomers, an N-oxide thereof, or a pharmaceutically acceptable salt thereof wherein Y is a phenyl group substituted with a chlorine atom at the 4-position.
16. The compound of claim 13 , an enantiomer or a mixture of its enantiomers, an N-oxide thereof, or a pharmaceutically acceptable salt thereof wherein R 1 is hydrogen and R 2 is a methyl group.
17. The compound of claim 13 , an enantiomer or a mixture of its enantiomers, an N-oxide thereof, or a pharmaceutically acceptable salt thereof wherein R 3 and R 4 are hydrogen.
18. The compound of any one of claims 13 - 17 , an enantiomer or a mixture of its enantiomers, an N-oxide thereof, or a pharmaceutically acceptable salt thereof which is said compound of the formula (Ib).
19. The compound of claim 13 , which is (4-chloro-phenyl)-(2-indazol-2-yl-6-methyl-pyrimidin-4-yl)-amine, an enantiomer or a mixture of its enantiomers, an N-oxide thereof, or a pharmaceutically acceptable salt thereof.
20. A pharmaceutical composition comprising:
a therapeutically effective amount of the compound of claim 13 or 19 , an enantiomer or a mixture of its enantiomers, an N-oxide thereof, or a pharmaceutically acceptable salt thereof together; and
at least one pharmaceutically acceptable carrier or diluent.